S. Shariat

Using ambient AI in clinical consultations: reframing policy around clinical audit and patient safety

Recent work has mapped what is legally permitted, commercially practiced, and technically coming for ambient AI in clinical care, yet it has not addressed the prior question of what the recording is for. This Perspective offers a policy argument, not an empirical evaluation. Documentation, workflow efficiency, patient...

Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease.

Impact of Gleason Grade at the Positive Surgical Margin on Biochemical Recurrence After Radical Prostatectomy in pT2N0 Prostate Cancer.

GG at the PSM independently predicts BCR, with the strongest effect in lower-grade tumors (ISUP 1-2; HR 7.08 for GG4), attenuated in high-grade disease (HR 2.98).

Cancer-specific mortality in high-risk or very high-risk prostate cancer patients treated with focal therapy vs. radical prostatectomy.

INTRODUCTION Focal therapy (FT) in high-risk or very high-risk prostate cancer (CaP) is not guideline-recommended. However, it may be occasionally used, but its effect on cancer-specific mortality (CSM) relative to standard treatment options such as radical prostatectomy (RP) is unknown and was addressed in the present...

Diet and risk of bladder cancer: a systematic review of epidemiological evidence.

Available evidence does not support a strong or consistent association between dietary factors and bladder cancer (BC) risk, and patients should be informed that dietary modifications alone are unlikely to meaningfully alter their BC risk.

Predictive biomarkers for immunotherapy response in renal cell carcinoma: why have they failed?

Current limitations in the development of consistent predictive biomarkers are outlined and future progress will require biomarker-stratified prospective trial designs with prespecified endpoints and rigorous external validation to establish clinically meaningful biomarkers.